Results 71 to 80 of about 111,076 (331)

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Epidemiology and clinical characteristics of mesothelioma in the Chinese population: a multicenter study

Therapeutic Advances in Medical Oncology
Background: Mesothelioma is a rare and highly aggressive tumor that causes severe damage. However, there is a lack of systematic reports on the incidence and clinical characteristics of mesothelioma in the Chinese population.
Shengjie Yang, Yue Hao, Ke Wang, Haipeng Xu, Long Huang, Ling Xu, Rui Meng, Bihui Li, Jianhui Huang, Youcai Zhu, Xuefei Shi, Dong Wang, Ziyan Yang, Zhenying Guo, Jingxun Wu, Wenfeng Li, Jianfei Fu, Yinghua Ji, Zongyang Yu, Miao Li, Huijing Feng, Lin Wang, Qing Ji, Wenjun Tang, Zhengbo Song, Chunwei Xu, Qian Wang   +26 more
doaj   +1 more source

Concomitant Nephrotic Syndrome and Cryoglobulinemia in a Case of Malignant Mesothelioma

Case Reports in Nephrology, 2022
Malignant pleural mesothelioma is rarely associated with nephrotic syndrome. Cryoglobulinemia is found in various pathological statuses, such as hepatitis C virus infection but rarely in malignant neoplasms.
Kei Nagai, Hiroaki Tachi, Kohei Inoue, Atsushi Ueda   +3 more
doaj   +1 more source

Malignant Peritoneal Mesothelioma With EWSR1-ATF1 Fusion: A Case Report

JTO Clinical and Research Reports, 2021
Malignant mesothelioma with EWSR1-ATF1 fusion is a rare malignancy described in young adults without asbestos exposure. To the best of our knowledge, outcomes to local and systemic therapies for this subtype of malignant mesothelioma have not been ...
Helen Ke, MBBS (Hons), Anthony J. Gill, AM, MBBS, FRCPA, Catriona McKenzie, MBBS (Hons1), FRCPA, James G. Kench, MBBS, Bsc(Med), FRCPA, Renee C.F. Chan, MBBS(Hons1), FRCPA, Nick Pavlakis, BSc, MBBS, MMed(Clin. Epi), PhD, FRACP, Michael Fulham, MBBS(Hons), FRACP, Cherry Koh, MBBS (Hons), MS, FRACS, Steven Kao, BHB, MBChB, PhD, FRACP   +8 more
doaj   +1 more source

Inhibition of cyclin-dependent kinase 7 down-regulates yes-associated protein expression in mesothelioma cells. [PDF]

, 2020
Cyclin-dependent kinase 7 (CDK7) is a protein kinase that plays a major role in transcription initiation. Yes-associated protein (YAP) is a main effector of the Hippo/YAP signalling pathway.
Bin, Hu, Chan, Geraldine, Jablons, David M, Kyoyama, Hiroyuki, Li, Hui, Liu, Luwei, Liu, Shu, Miao, Jinbai, Urisman, Anatoly, Wang, Yucheng, Xu, Zhidong, Yang, Yi-Lin, You, Liang   +12 more
core  

Introduction [PDF]

, 2017
Contains fulltext : 190586.pdf (publisher's version ) (Open Access)20 ...
Devos, Isabelle, Janssens, Angélique
core   +3 more sources

Organ‐Specific and Conserved Regulatory Logic Orchestrates Gene Expression in the Embryonic Mesothelium

Advanced Science, EarlyView.
Integrated multi‐omic profiling maps the gene‐regulatory landscape of the coelomic mesothelium across heart, lung, and pancreas. A cardiac‐restricted regulatory program is uncovered in which TBX20 activates heart mesothelial (epicardial) cis‐regulatory elements, while MAF emerges as a conserved regulator of mesothelial identity.
Quang Minh Dang, Nicola Smart, Andia Nicole Redpath, Joaquim Miguel Vieira   +3 more
wiley   +1 more source

Durable complete response in a patient with BRAF-mutated advanced melanoma with ocular and skin toxicities from BRAF/MEK targeted therapy after immune checkpoint inhibitor treatment: a case report

Dermatology Reports
Here we report the case of a woman suffering from advanced melanoma who developed severe toxicities with BRAF and MEK inhibitors (BRAFis, MEKis), given as second-line therapy after failure of immunotherapy, who achieved a complete and durable response ...
Carlotta Bertolina, Marinella Bertolotti, Claudia Leporati, Antonina Maria De Angelis, Sara Delfanti, Luigi Cerbone, Marco Ghiglione, Federica Grosso   +7 more
doaj   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source